ARGX Reports $1.2B Revenue, $0.85 EPS, +42% YoY, Launches VYVGART Hytrulo for CIDP, Expands MG Pipeline, ADAPT OCULUS Meets Primary Endpoint, FDA Priority Review for oMG, ADHERE Shows 87.5% Early Benefit in Naïve CIDP, Phase 3 ADAPT SERON Positive Across Serotypes, ADAPT Jr Achie
argenx SE American Depositary Shares · Now $836.09
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS